Autres langues GenSight Biologics S.A.

Actions

SIGHT

FR0013183985

Temps réel Euronext Paris Autres places de cotation 09:00:03 22/05/2024			Varia. 5j.	Varia. 1 janv.
0,403 ^EUR	+2,28 %		-1,23 %	-12,39 %

07/05	GenSight Biologics S A : lève 9 millions d'euros et reprend sa cotation	AO
07/05	FOMO is Back

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

GenSight Biologics S A : AGM 2024 – Board nominees	07/05
GenSight Biologics S A : Securities Note	07/05
GenSight Biologics S A : Terms of availability of prospectuses	07/05
GenSight Biologics Announces the Availability of a Prospectus in Connection With the Listing of New Shares on Euronext Paris	07/05
GenSight Biologics: Annual General Meeting on May 29, 2024	07/05
GenSight Biologics Announces a Successful Offering for an Amount Over €9.2 Million	07/05
GenSight Biologics S.A. announced that it expects to receive ?1.546199 million in funding	07/05
GenSight Biologics S A : Annual General Meeting on May 29, 2024	06/05
GenSight Biologics S A : Inside Information / News release on accounts, results	18/04
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document	18/04
GenSight Biologics S A : Announces the Filing of its 2023 Universal Registration Document	17/04
GenSight : visibilité financière assurée jusqu'à fin avril	05/04
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update	04/04
GenSight Biologics Announces its 2024 Financial Calendar	04/04
GenSight Biologics S A : Reports Cash Position as of March 31, 2024, and Provides Business Update	04/04
GenSight Biologics S A : Announces Its 2024 Financial Calendar	04/04
GenSight : le titre chute, visibilité financière limitée	25/03
GenSight Biologics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results	22/03
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration	20/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues GenSight Biologics S.A.

Actions

SIGHT

FR0013183985

Autres langues

Filtres